SBFMW
Sunshine Biopharma Inc.Warrants of Sunshine Biopharma Inc. · SBFM stock page →
—
Market cap
$380.5K
Nano cap
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read BEARISH 2 reports · latest
Balance 1 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 2/2
Price
Daily candles with volume.
No data for this timeframe.
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 0 added (0 new), 1 trimmed or exited.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| UBS Group AG | TRIM | $546.00 |
| CITADEL ADVISORS LLC | TRIM | $1.7K |
| UBS Group AG | DOUBLED | $6.0K |
| UBS Group AG | TRIM | $208.00 |
| CITADEL ADVISORS LLC | TRIM | $5.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 23, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 23, 2026
Trading halt
Trading Halt: SBFMW — T1 (News Pending)
Sunshine Biopharma Inc. Wt | Market: NASDAQ | Code: T1 — News Pending
May 10, 2026
Trial readout
T-90d Trial Readout: Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) (Phase 2)
Trial: Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis Sponsor: Sunshine Guojian Pharmaceutical…
May 3, 2026
Trial readout
T-90d Trial Readout: Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) (Phase 2)
Trial: Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis Sponsor: Sunshine Guojian Pharmaceutical…
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $9.6M |
| Next Q | — | — | — | $9.8M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | — | — | — | $45.0M |
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Trading halts
| Oct 23, 2026 | Resumption Scheduled | Resumed |
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Trading halt
🔒 Fresh data, subscribers only
Jun 30, 2026 Inst.
May 19, 2026 SEC UBS Group AG — TRIM
11,879 shares ($546.00)
Sunshine Biopharma has completed a $6.0 million priced offering, issuing 11,160,000 Common Units (each with one share…
424B4 — Impact 6/10
Sunshine Biopharma reported fiscal 2025 revenue of $36.3 million, a 4.1% increase from 2024, driven by new product…
8-K — Impact 6/10
Sep 30, 2025 Inst.
CITADEL ADVISORS LLC — TRIM
12,073 shares ($1.7K)
SecBot reports
2 filings · 0 bullish · 1 bearish · 1 mixed- BEARISH 424B4May 19, 2026
Sunshine Biopharma has completed a $6.0 million priced offering, issuing 11,160,000 Common Units…
Massive share issuance will likely pressure the stock price due to immediate overhang. The warrants (24M Series C at $0.50) add further potential dilution. Monitor for any Nasdaq compliance update…
- MIXED 8-KApr 9, 2026
Sunshine Biopharma reported fiscal 2025 revenue of $36.3 million, a 4.1% increase from 2024…
Monitor 2026 quarterly filings to verify if the cost-reduction initiatives yield the expected $2–3 million in savings and whether revenue growth accelerates beyond 4.1%.
All SBFMW filing & press-release reports (2)
- 424B4 reportMay 19, 2026
- 8-K reportApr 9, 2026